- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04059796
Comparison of Gemini III Rev 2 Implanted in Conjunction With an Approved IOL vs Eyes Implanted With an Approved IOL
Clinical Investigation of OMEGA Gemini Capsule, Model Gemini Capsule 3 Rev 2 in Combination With a Commercially Available, FDA Approved Monofocal or Toric Intraocular Lens
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects will be randomly assigned to which eye will receive the Omega capsule Gemini 3 with an approved monofocal or Toric intraocular lens. Fellow eyes will receive an approved monofocal or Toric IOL (no Omega capsule).
Eyes randomized to receive one of the Gemini capsules (both models) will be eligible to have a secondary procedure (post 1-month postoperative visit) to correct refractive error.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
San José, Costa Rica
- Clinica 20/20
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 40 years of age or older at the time of surgery diagnosed with bilateral cataracts
- Able to understand and sign an informed consent
- Willing and able to complete all study visits and assessments required for the study
- Calculated lens power within the available range
- Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or without a glare source present
- Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag fixated IOL implantation
- Potential postop visual acuity of 20/25 or better in the judgment of the surgeon
- Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography
- Clear intraocular media other than cataract
- Preop endothelial cell density of 2000 cells/mm2 or more
Exclusion Criteria:
- Subject's best corrected vision is light perception or no light perception in either eye
- Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal and macular examination.
- Orbital abnormalities, such as thyroid related orbitopathy, causing significant exophthalmos.
- Eyelid abnormalities causing lagophthalmos.
- Significant anterior blepharitis or meibomian gland dysfunction
- Corneal abnormalities or conditions, other than regular topographic corneal astigmatism
- Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium)
- Abnormalities of the iris including trans-illumination defects
- Pupil abnormalities (abnormally shaped, fixed or non-reactive)
- Pharmacologic dilation less than 7 mm
- Axial length <22.5mm
- Lens thickness <4.1 mm
- Anterior chamber depth >2.8mm
- Extremely shallow anterior chamber <2.0mm
- Prior ocular surgery
- Epiretinal membrane
- Macular edema
- Retinal tears including operculated holes
- Amblyopia
- Glaucoma of any kind
- Pseudoexfoliation syndrome
- History of uveitis/iritis
- Diabetic retinopathy
- Acute, chronic or uncontrolled systemic or ocular disease that may confound the results of the study (including rheumatologic conditions such as Rheumatoid arthritis, ankylosing spondyliltis, Sjögren's syndrome, and neurologic conditions such as optic neuritis or multiple sclerosis).
- Prior or anticipated use of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) or similar medications
- Average Keratometry <38D or > 48D by topography
- Any pathology of the zonules including evidence of zonular weakness, zonular instability, zonular damage, or coloboma effecting zonules.
- History of ocular trauma
- Pregnant, lactating, or has another condition with associated fluctuation of hormones that could lead to refractive changes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Study Eye
Study device in conjunction with an approved monofocal or toric IOL after cataract extraction
|
Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
|
ACTIVE_COMPARATOR: Control Eye
approved monofocal or toric IOL after cataract extraction
|
Control eyes will receive an approved monofocal or toric IOL post cataract extraction
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absence of fusion of peripheral anterior and posterior capsule to the intraocular lens
Time Frame: 6 month Postop Visit
|
Via dilated slit lamp examination subjects will be assessed for anterior and posterior Via dilated slit lamp examination subjects will be assessed for anterior and posterior fusion of the IOL to the capsular bag with a dichotomous "Yes/No" response.
|
6 month Postop Visit
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Gemini III Rev 2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract
-
Fundación Pública Andaluza para la Investigación...CompletedCataract | Cataract Mature | Cataract, Nuclear
-
Johannes Kepler University of LinzCompletedCataract Complicated | Cataract Complications OperationsAustria
-
Gemini Eye ClinicRecruitingBilateral Cataract | Unilateral CataractCzechia
-
Universitaire Ziekenhuizen KU LeuvenLaboratoires TheaRecruiting
-
Omer Othman AbdullahCompletedCongenital Cataract | Pediatric CataractIraq
-
Yonsei UniversityCompletedCataract PatientsKorea, Republic of
-
Johannes Kepler University of LinzRecruitingAphakia | Secondary Cataract Surgery | Complicated Cataract SurgeryAustria
-
Advanced Center for Eyecare GlobalNot yet recruiting
-
Vienna Institute for Research in Ocular SurgeryRecruiting
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruitingCataract ExtractionChina
Clinical Trials on Control Eye
-
Omega OphthalmicsCompleted
-
Cairo UniversityCompleted
-
University of Alabama at BirminghamPfizerCompletedVision | Eye Disease | Eye CareUnited States
-
VA Office of Research and DevelopmentCompleted
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited Kingdom
-
Dijklander ZiekenhuisRecruitingDiabetes Mellitus | Neuropathic PainNetherlands
-
University of ArkansasWithdrawnMeibomian Gland DysfunctionUnited States
-
Kuopio University HospitalBusiness Finland; 4Pharma Ltd.; Finnsusp Ltd.Completed
-
Xiaoliang GanUnknownChild | Anesthesia | AgitationChina
-
University Hospital, LilleNot yet recruitingPost Traumatic Stress Disorder